secwatch.observer — SEC 8-K summary
======================================

Issuer:     Keros Therapeutics, Inc. (KROS)
CIK:        0001664710
Form:       8-K
Filed at:   2022-01-31T23:59:59+00:00
Accession:  0001664710-22-000002
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Keros Therapeutics appoints Christopher Rovaldi as COO effective Feb 1, 2022
----------------------------------------------------------------------------

- Christopher Rovaldi appointed Chief Operating Officer, effective February 1, 2022.
- Rovaldi brings 20+ years experience, most recently as consultant and president of NS Biopharma Consulting.
- Previously held senior roles at Acceleron Pharma (2007-2018), including SVP Program Management and Operations.
- Initial annual base salary of $470,000; target bonus 50% of salary; option to purchase 100,000 shares.
- Severance includes 9-12 months base salary and COBRA, with equity acceleration upon change of control termination.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1664710/000166471022000002/0001664710-22-000002-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1664710/000166471022000002/kros-20220128.htm
  HTML page:      https://secwatch.observer/filing/0001664710-22-000002

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer